Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ for the ...

Generated $52.5 million in net revenue from sales of LUMRYZ, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since ...